| __timestamp | Alkermes plc | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 7459000 |
| Thursday, January 1, 2015 | 4019000 | 11831000 |
| Friday, January 1, 2016 | 2301000 | 25705000 |
| Sunday, January 1, 2017 | 7232000 | 46181000 |
| Monday, January 1, 2018 | 68895000 | 59497000 |
| Tuesday, January 1, 2019 | 52816000 | 65003000 |
| Wednesday, January 1, 2020 | 1946000 | 74506000 |
| Friday, January 1, 2021 | 1020000 | 126006000 |
| Saturday, January 1, 2022 | 393842000 | 126215000 |
| Sunday, January 1, 2023 | 270806000 | 120161000 |
| Monday, January 1, 2024 | 245326000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Alkermes plc and Protagonist Therapeutics, Inc. have demonstrated contrasting yet intriguing R&D investment strategies.
From 2014 to 2023, Alkermes plc's R&D expenses surged by over 3,400%, peaking in 2022 with a remarkable 394 million USD. This reflects a strategic pivot towards aggressive innovation. In contrast, Protagonist Therapeutics, Inc. maintained a steady increase, with a notable 1,590% rise, reaching its zenith in 2022 with 126 million USD.
These trends underscore the dynamic nature of R&D investments in the biopharma sector, where strategic financial commitments can lead to groundbreaking advancements. As the industry continues to evolve, understanding these patterns offers valuable insights into the future of drug development and therapeutic breakthroughs.
Research and Development: Comparing Key Metrics for AbbVie Inc. and Alkermes plc
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Protagonist Therapeutics, Inc.
Sanofi vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Alkermes plc
R&D Spending Showdown: United Therapeutics Corporation vs Alkermes plc
R&D Spending Showdown: Incyte Corporation vs Protagonist Therapeutics, Inc.
Research and Development Investment: Pharming Group N.V. vs Alkermes plc
Research and Development Investment: Corcept Therapeutics Incorporated vs Alkermes plc
Research and Development Investment: Alkermes plc vs MiMedx Group, Inc.
Amneal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Protagonist Therapeutics, Inc. vs MiMedx Group, Inc.: Strategic Focus on R&D Spending